Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05407805 · ClinicalTrials.gov registry record

A Study to Learn About Sickle Cell Disease In Adult Patients

A clinical trial of Sickle Cell Disease, sponsored by Pfizer.

Completed
Registry status
98
Enrollment target
5
Study locations

NCT05407805 is a study of Sickle Cell Disease that has completed, run by Pfizer. The registered enrollment target is 98 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05407805, a study of Sickle Cell Disease, has completed, sponsored by Pfizer.

COMPLETED
Registry status
98 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment. SCD is a type of condition when there are fewer red blood cells to carry oxygen around the body. This disease can be passed on from parent to child and may cause pain, infections and damage to organs. This study is seeking participants who: * are confirmed with SCD * are on a stable regimen of disease changing treatment or have not received any disease changing treatment before the start of the study and do not plan any changes in their treatment during the 6-month study observation period For 6 months, participants will be asked to complete a daily electronic diary to report on their experience in the past 24 hours with sickle cell pain crisis (if they got any treatment and what medications they took), worst pain, worst tiredness, and their ability to perform usual physical activities. We will compare the experiences of people who are taking SCD-modifying therapy to those that are not taking a SCD-modifying therapy.

Conditions Studied

Sickle Cell Disease

Interventions

  • OTHER Electronic Diary

Study Locations (5)

Maryland

  • Mid-Atlantic Permanente Medical Group Largo Medical Center - Largo
  • Mid-Atlantic Permanente Medical Group Largo Medical Center - Upper Marlboro

Florida

  • Foundation for Sickle Cell Disease Research - Hollywood

Massachusetts

  • Sanguine Biosciences, Inc. - Waltham

New York

  • Cohen Children's Medical Center - New Hyde Park

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2022-02-10
Est. Completion 2024-06-24

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05407805

The ClinicalTrials.gov registry entry for NCT05407805 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Electronic Diary is the first listed.

NCT05407805 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05407805 about?

NCT05407805 is a clinical study titled "A Study to Learn About Sickle Cell Disease In Adult Patients". The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment. SCD is a type of condition when there are fewer red blood cells to carry oxygen around ...

What is the current status of trial NCT05407805?

This trial is currently completed. The enrollment target is 98 participants. The study started on 2022-02-10. Estimated completion is 2024-06-24.

What conditions does trial NCT05407805 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT05407805?

The interventions under investigation include: Electronic Diary (OTHER).

Who is sponsoring clinical trial NCT05407805?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05407805 being conducted?

This trial has 5 study locations across Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.